SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects, so that patients can achieve immune balance and live beyond their inflammation.
AP1189, our product candidate selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression that is associated with most of the available anti-inflammatory therapies. These immunosuppressive approaches can lead to opportunistic infections and other serious side effects.
Medicon Village AB Scheelevägen 2, 22381 Lund – Sweden
July 12, 2022Stock exchange(s)